Prostate Cancer - Results from #680

Is There a Place for De-escalating Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer? July 4, 2024

Targeted Investigational Treatment Analysis of Novel Anti-androgen (TITAN) study: ultralow prostate-specific antigen decline with apalutamide plus androgen-deprivation therapy. July 4, 2024

Clinical Impact of Contouring Variability for Prostate Cancer Tumor Boost. July 4, 2024

The role of a radiopaque peri-rectal hydrogel spacer in aiding accurate daily image-guidance for prostate stereotactic radiotherapy. July 4, 2024

Comparative analysis of genetic risk scores for predicting biochemical recurrence in prostate cancer patients after radical prostatectomy. July 4, 2024

Rare pathogenic structural variants show potential to enhance prostate cancer germline testing for African men. July 4, 2024

Novel mRNA adjuvant ImmunER enhances prostate cancer tumor-associated antigen mRNA therapy via augmenting T cell activity. July 4, 2024

Predicting Peak Productivity in Urologic Medicare Practice via Work-Relative Value Units July 3, 2024

Full-Life Technologies Granted FDA Fast Track Designation for 225Ac-FL-020 for the Treatment of Metastatic Castration-Resistant Prostate Cancer July 3, 2024

Microsatellite Instability, Tumor Mutational Burden, and Response to Immune Checkpoint Blockade in Patients with Prostate Cancer. July 3, 2024

Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the United States. July 3, 2024

Social integration and long-term physical and psychosocial quality of life among prostate cancer survivors in the Health Professionals Follow-up Study. July 3, 2024

Epidemiology, treatment patterns, and clinical outcomes in de novo oligometastatic hormone-sensitive prostate cancer. July 3, 2024

Fluorine-18 Prostate-Specific Membrane Antigen-1007 PET/CT vs Multiparametric MRI for Locoregional Staging of Prostate Cancer. July 3, 2024

A selective CutMix approach improves generalizability of deep learning-based grading and risk assessment of prostate cancer. July 3, 2024

Enhancing circulatory myokines and extracellular vesicle uptake with targeted exercise in patients with prostate cancer (the MYEX trial): a single-group crossover study. July 3, 2024

Imaging with [89Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial. July 3, 2024

U.S. Food and Drug Administration (FDA) Approves FoundationOne®Liquid CDx as a Companion Diagnostic for AKEEGA® (niraparib and abiraterone acetate) for Patients with BRCA-Positive Metastatic Castration-Resistant Prostate Cancer July 2, 2024

PSMA-PET follow-up to assess response in patients not receiving PSMA therapy: Is there value beyond localization of disease? July 2, 2024

Whole pelvis vs. hemi pelvis elective nodal radiotherapy in patients with PSMA-positive nodal recurrence after radical prostatectomy - a retrospective multi-institutional propensity score analysis. July 2, 2024

Page 35 of 1437